SCHEMBL505879

SCHEMBL505879

O=C(O)c1ccc(-c2cccc(F)c2)c(F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.56
AKR1C2 P52895 1/20 0.56
AXL P30530 1/20 0.49
TTR P02766 2/20 0.49
KDM4E B2RXH2 1/20 0.49
MEN1 O00255 1/20 0.49
USP2 O75604 1/20 0.49
ALDH1A1 P00352 1/20 0.49
DHFR P00374 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
LMNA P02545 1/20 0.49
ALB P02768 1/20 0.49
HMGB1 P09429 1/20 0.49
HPGD P15428 1/20 0.49
CXCL12 P48061 1/20 0.49
KMT2A Q03164 1/20 0.49
HIF1A Q16665 1/20 0.49
SLC22A6 Q4U2R8 1/20 0.49
ACMSD Q8TDX5 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL120358 0.87 AKR1C3 (0.63) AKR1C3AKR1C2AXLTTRKDM4E
SCHEMBL29473809 0.86 RARB (0.56) AKR1C3AKR1C2AXLTTRMEN1
SCHEMBL2041007 0.86 RARB (0.56) AKR1C3AKR1C2AXLTTRMEN1
SCHEMBL3642916 0.85 AKR1C3 (0.59) AKR1C3AKR1C2AXLTTRKDM4E
SCHEMBL30189377 0.84 RARB (0.51) AKR1C3AKR1C2AXLTTRKDM4E
SCHEMBL14917120 0.84 RARB (0.51) AKR1C3AKR1C2AXLTTRKDM4E
SCHEMBL4539558 0.84 AKR1C3 (0.55) AKR1C3AKR1C2KDM4EALDH1A1RARB
SCHEMBL25606034 0.84 AKR1C3 (0.53) AKR1C3AKR1C2AXLTTRKMT2A
SCHEMBL2562268 0.83 AKR1C3 (0.63) AKR1C3AKR1C2AXLLMNARARB
SCHEMBL2562437 0.81 TRIM24 (0.63) AKR1C3AKR1C2AXLTTRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9946847-B2 Libraries of compounds having desired properties and methods for making and using them BIOBLOCKS INC. (US) 2018-04-17 US disclosed
US-9946847-B2 Libraries of compounds having desired properties and methods for making and using them BIOBLOCKS INC. (US) 2018-04-17 US disclosed
US-20150269356-A1 LIBRARIES OF COMPOUNDS HAVING DESIRED PROPERTIES AND METHODS FOR MAKING AND USING THEM BIOBLOCKS INC (US) 2015-09-24 US disclosed
US-20150269356-A1 LIBRARIES OF COMPOUNDS HAVING DESIRED PROPERTIES AND METHODS FOR MAKING AND USING THEM BIOBLOCKS INC (US) 2015-09-24 US disclosed
US-9006454-B2 Dihydroorotate dehydrogenase inhibitors MERCK SERONO S.A. (CH) 2015-04-14 US disclosed
WO-2014047463-A2 LIBRARIES OF COMPOUNDS HAVING DESIRED PROPERTIES AND METHODS FOR MAKING AND USING THEM BIOBLOCKS, INC. (US) 2014-03-27 WO disclosed
US-20120028959-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS MERCK SERONO S.A. (CH) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028959-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS DHODH, FH, DPYD AKR1C3 129/4885AKR1C2 119/4885AXL 4684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.